

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/667,119	09/17/2003	Ian William Mills	PC25321A	9342
28523	7590 02/13/2006		EXAMINER	
PFIZER INC.			HENLEY III, RAYMOND J	
PATENT DEPARTMENT, MS8260-1611 EASTERN POINT ROAD			ART UNIT	PAPER NUMBER
GROTON, C			1614	
			DATE MAILED: 02/13/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/667,119	MILLS, IAN WILLIAM				
Office Action Summary	Examiner	Art Unit				
	Raymond J. Henley III	1614				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim 11 apply and will expire SIX (6) MONTHS from cause the application to become ABANDONET	√. lely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on	_ ·					
,— · · · · · · · · · · · · · · · · · · ·	action is non-final.					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	33 O.G. 213.				
Disposition of Claims						
4) Claim(s) <u>1-4</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-4</u> is/are rejected.)⊠ Claim(s) <u>1-4</u> is/are rejected.					
	—					
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9)⊠ The specification is objected to by the Examiner	r.					
10)⊠ The drawing(s) filed on <u>17 September 2003</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).				
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive ı (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4)	(PTO-413)				

Art Unit: 1614

CLAIMS 1-4 ARE PRESENTED FOR EXAMINATION

Applicant's Information Disclosure Statements filed September 17, 2003, February 4, 2004 and May 31, 2005 have been received and entered into the application. As reflected by the attached, completed copies of forms conforming with form PTO-FB-A820 (3 sheets total), the Examiner has considered the cited references.

Improper Incorporation by Reference

The attempt to incorporate subject matter into this application by reference to PCT publications WO 98/30560 and WO 01/64672 is ineffective because of the following reasons.

The incorporation of essential material in the specification by reference to a foreign application or patent, or to a publication is improper.

Applicant is required to amend the disclosure to include the material incorporated by reference, if the material is relied upon to overcome any objection, rejection, or other requirement imposed by the Office. The amendment must be accompanied by a statement executed by the applicant, or a practitioner representing the applicant, stating that the material being inserted is the material previously incorporated by reference and that the amendment contains no new matter. 37 CFR 1.57(f).

Claim Objection

Claim 1 is objected to because given a first occurrence of an acronym, its full meaning should also be present. Thus, at line 1 of claim1, "LUTS" should be amended to read "Lower Urinary Tract Symptoms (LUTS)..." The same should be applied to "OAB" at line 1 of the claim.

Art Unit: 1614

Specification

The specification is objected to under MPEP § 608.01(f) because it fails to include a section entitled "Brief Description of the Drawings" and appropriate subject matter there-under which clearly describes each of the drawings, including views, presented by Applicant.

Claim Rejection - 35 USC § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-4 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

"The primary purpose of this requirement of definiteness of claim language is to ensure that the scope of the claims is clear so the public is informed of the boundaries of what constitutes infringement of the patent. A secondary purpose is to provide a clear measure of what applicants regard as the invention so that it can be determined whether the claimed invention meets all the criteria for patentability and whether the specification meets the criteria of 35 U.S.C. 112, first paragraph with respect to the claimed invention." (MPEP 2173).

The term "derivative" in claims 1, and thus its dependents, is a relative term which renders the claim indefinite. In particular, "derivatives" does not particularly point out the degree or type of derivation that a given compound may have in relation to the parent compound and still be considered a "derivative" as intended by Applicant. Applicant has failed to provide any specific definition for this term in the present specification. Lacking a clear meaning of the

Art Unit: 1614

term "derivative", the skilled artisan would not be reasonably apprised of the metes and bounds of the subject matter for which Applicant seeks patent protection.

In order to overcome this rejection, Applicant may either wish to delete the term "derivative" or include specific derivative form that have basis in the present specification.

Claim Rejection - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over PCT Publications WO 98/30560 and WO 01/64672, and Applicant's acknowledgment thereof at page 1 of the present specification, in view of Cecil, Textbook of Medicine (hereinafter "Cecil").

As acknowledged by Applicant at page 1 of the specification, PCT Publications WO 98/30560 and WO 01/64672 teach the presently claimed quinazoline compound, as well as its mesylate form, for the treatment of benign prostatic hyperplasia, (see also '560 at the abstract, page 12, line 9 and Example 19 at pages 36-37 and the '672 document at the abstract, page 5 at lines 9-14 and Example 2 at pages 17-18).

The difference between the above and the claimed subject matter lies in that neither reference highlights the treatment of LUTS associated with OAB, with or without concomitant detrusor over activity; pelvic floor dysfunction or chronic prostatitis.

However, the difference between the subject matter sought to be patented and the prior art is such that the subject matter as a whole would have been obvious at the time the invention

Art Unit: 1614

was made to a person having ordinary skill in the art to which said subject matter pertains because, as taught by Cecil, page 637, col. 1, last paragraph, prostatic hyperplasia is" only one facet of a larger syndrome consisting of both irritative and obstructive *lower urinary tract symptoms*" (emphasis added). Thus, the teaching of benign prostatic hyperplasia in the primary references would have been appreciated by one of ordinary skill to include LUTS as well. Also, because the primary references teach benign prostatic hyperplasia in general, and Cecil teaches "bladder dysfunction" in general (see the fourth line from bottom of col. 1 at page 637), it is believed that such would encompass the other specific conditions presented in the claims, in the absence of evidence to the contrary.

None of the claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Raymond J. Henley III whose telephone number is 571-272-0575. The examiner can normally be reached on M-F, 8:30 am to 4:00 pm Eastern Time.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Raymond J Henley III Primary Examiner

Art Unit 1614